Philip Bielefeld

Philip Bielefeld

Auto-generated profile, based on publicly available information

Philip Bielefeld

Internal Medicine and Systemic Diseases Department (Medicine Interne 2), Dijon University hospital, Dijon, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
GMGeorgina Maalouf
Georgina Maalouf
AAAnaïs Andrillon
Anaïs Andrillon
MLMathilde Leclercq
Mathilde Leclercq
PSPascal Sève
Pascal Sève
PBPhilip Bielefeld
Philip Bielefeld
DSDavid SAADOUN
David SAADOUN

1 June 2014 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
PBP. Bielefeld
P. Bielefeld
DSDavid SAADOUN
David SAADOUN
HDH. Devilliers
H. Devilliers
AMA. Muselier
A. Muselier
CDC. Deschasse
C. Deschasse
JBJ.-F. Besancenot
J.-F. Besancenot

1 December 2011 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
JVJ. Vinit
J. Vinit
SBS. Berthier
S. Berthier
JBJ.-F. Besancenot
J.-F. Besancenot
SASylvain Audia
Sylvain Audia
PBP. Bielefeld
P. Bielefeld
BBBernard Bonnotte
Bernard Bonnotte

1 June 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
HDH. Devilliers
H. Devilliers
ZAZ. Amoura
Z. Amoura
SASylvain Audia
Sylvain Audia
MJMeenakshi Jolly
Meenakshi Jolly
PBP. Bielefeld
P. Bielefeld
JBJ.-F. Besancenot
J.-F. Besancenot
Background Little is published on comparative responsiveness of generic and disease specific Patients reported outcomes (PRO) tool in systemic lupus erythematosus (SLE). Objectives To determine and compare the responsiveness and minimally clinical important difference (MCID) of a generic and disease specific PRO measure in SLE. Methods SLE patients from a French multicenter study were clinically assessed for activity (SELENA-SLEDAI) at baseline, MOS Short Form 36 (SF-36), LupusQoL, and an overall health status item at baseline (D0), 3 (M3) and 6 (M6) months. Self-reported overall health status item enquired about the impact of lupus on overall health since past visit. Its 7 response options were: -3 “much improved”, -2 “moderately improved”, -1 “minimally improved”, 0 “the same”, +1 “minimally worse”, +2 “moderately worse” and +3 “much worse”. Responsiveness and MCID for SF-36 and LupusQoL domains were determined against +1 or -1 change in overall health status (Anchor-based approach). Descriptives and standardized response mean (SRM) of variations in SF36 and LupusQoL domains were estimated and compared using mixed models methods. Results We included 185 SLE patients. Mean (SD) age and SELENA-SLEDAI were 39.6 (10.6) years and 2.6 (3.5). We analyzed 3 time-point data (515 visits) and two consecutive time-point data (306 visits). LupusQoL “Body Image”, “Fatigue”, and “Burden to others” domains did not change significantly with “worsening” in overall health status; while LupusQoL “body image”, and SF-36 “General Health” and “Physical Functioning” domains did not change significantly with an “improvement” in overall health status. SRM in comparable domains of SF-36 and LupusQoL were similar, except for improvement in LupusQoL Physical Health. SRM ranged from small-moderate for all domains on both measures (table). Conclusions Both SF-36 and LupusQoL show responsiveness in most domains with change in overall health status. LupusQoL is more responsive to improvement, while SF-36 is more responsive to worsening in overall health status. Disclosure of Interest H. Devilliers Consultant for: GlaxoSmithKline, Z. Amoura Consultant for: Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Neovacs, Roche, Teva Pharmaceuticals, and UCB Pharma, S. Audia: None Declared, M. Jolly Consultant for: GSK, Medimmune, P. Bielefeld: None Declared, L. Arnaud Consultant for: Amgen, C. Binquet: None Declared, J.-F. Besancenot: None Declared